SCHEMBL26656339

SCHEMBL26656339

CCC1Cc2cc(F)ccc2N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRA2A P08913 4/20 0.41
▸ ADRA2B P18089 4/20 0.41
▸ ADRA2C P18825 4/20 0.41
▸ PNMT P11086 2/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ CREBBP Q92793 1/20 0.41
▸ HTR1D P28221 1/20 0.37
▸ HTR1B P28222 1/20 0.37
▸ SLC6A4 P31645 2/20 0.36
▸ HTR5A P47898 2/20 0.36
▸ AR P10275 3/20 0.34
▸ ACHE P22303 1/20 0.33
▸ CHRNB2 P17787 1/20 0.33
▸ CHRNB4 P30926 1/20 0.33
▸ CHRNA3 P32297 1/20 0.33
▸ CHRNA7 P36544 1/20 0.33
▸ CHRNA4 P43681 1/20 0.33
▸ ADRA1B P35368 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31404150 0.90 PNMT (0.35) ADRA2AADRA2BADRA2CPNMTBRD4
SCHEMBL550480 0.88 PNMT (0.46) ADRA2AADRA2BADRA2CPNMTBRD4
SCHEMBL27450456 0.78 ITGB3 (0.46) ADRA2AADRA2BADRA2CSLC6A4
SCHEMBL30681298 0.77 LMNA (0.46) BRD4CREBBPHTR5AARACHE
SCHEMBL8937088 0.77 LMNA (0.46) BRD4CREBBPHTR5AARACHE
SCHEMBL29529402 0.77 LMNA (0.46) BRD4CREBBPHTR5AARACHE
SCHEMBL29155359 0.74 HTR5A (0.40) ADRA2AADRA2BADRA2CHTR1DHTR1B
SCHEMBL22955423 0.74 CREBBP (0.59) ADRA2AADRA2BADRA2CPNMTBRD4
SCHEMBL549073 0.74 CREBBP (0.59) ADRA2AADRA2BADRA2CPNMTBRD4
SCHEMBL13072964 0.73 BRD4 (0.41) ADRA2AADRA2BADRA2CPNMTBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522582-B2 Antiviral indolinyl compounds and uses thereof GILEAD SCIENCES, INC. (US) 2026-01-13 — — US disclosed
EP-4526289-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-03-26 — — EP disclosed
CN-119546574-A Antiviral indolinyl compounds and uses thereof 吉利德科学公司 2025-02-28 — — CN disclosed
US-20240101529-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2024-03-28 — — US disclosed
WO-2023225162-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-11-23 — — WO disclosed
WO-2023225162-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101529-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF MAVS, IRF3, EIF2AK2 ADRA2A 4565/4885ADRA2B 4660/4885ADRA2C 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback